34 related articles for article (PubMed ID: 7682360)
1. Strategy of FK 506 therapy in liver transplant patients: effect of graft function.
Abu-Elmagd KM; Fung JJ; Alessiani M; Jain A; Takaya S; Venkataramanan R; Warty VS; Shannon W; Todo S; Tzakis A
Transplant Proc; 1991 Dec; 23(6):2771-4. PubMed ID: 1721272
[No Abstract] [Full Text] [Related]
2. Liver retransplantation in adults: overall results and determinant factors affecting the outcome.
Morel P; Rilo HL; Tzakis AG; Todo S; Gordon RD; Starzl TE
Transplant Proc; 1991 Dec; 23(6):3029-31. PubMed ID: 1721349
[No Abstract] [Full Text] [Related]
3. Renal function after conversion from cyclosporine to FK 506 in liver transplant patients.
McCauley J; Fung JJ; Brown H; Deballi P; Jain A; Todo S; Starzl TE
Transplant Proc; 1991 Dec; 23(6):3148-9. PubMed ID: 1721387
[No Abstract] [Full Text] [Related]
4. HLA matching effect in liver transplantation.
Yagihashi A; Kobayashi M; Noguchi K; Konno A; Yoshida Y; Terasawa K; Starzl TE; Iwaki Y
Transplant Proc; 1992 Dec; 24(6):2432-3. PubMed ID: 1281569
[No Abstract] [Full Text] [Related]
5. Conversion from cyclosporine to FK 506 in liver allograft recipients with cyclosporine-related complications.
Fung JJ; Todo S; Jain A; McCauley J; Alessiani M; Scotti C; Starzl TE
Transplant Proc; 1990 Feb; 22(1):6-12. PubMed ID: 1689901
[No Abstract] [Full Text] [Related]
6. Infections during a randomized trial comparing cyclosporine to FK 506 immunosuppression in liver transplantation.
Kusne S; Fung J; Alessiani M; Martin M; Torre-Cisneros J; Irish W; Ondick L; Jain A; Abu-Elmagd K; Takaya S
Transplant Proc; 1992 Feb; 24(1):429-30. PubMed ID: 1371626
[No Abstract] [Full Text] [Related]
7. Current status of FK 506 in liver transplantation.
Fung JJ; Todo S; Tzakis A; Alessiani M; Abu-Elmagd K; Jain A; Bronster O; Martin M; Gordon R; Starzl TE
Transplant Proc; 1991 Jun; 23(3):1902-5. PubMed ID: 1712133
[No Abstract] [Full Text] [Related]
8. Pharmacokinetics of cyclosporine and nephrotoxicity in orthotopic liver transplant patients rescued with FK 506.
Jain AB; Venkataramanan R; Fung J; Burckart G; Emeigh J; Diven W; Warty V; Abu-Elmagd K; Todo S; Alessiani M
Transplant Proc; 1991 Dec; 23(6):2777-9. PubMed ID: 1721274
[No Abstract] [Full Text] [Related]
9. Four-hour versus 24-hour intravenous infusion of FK 506 in liver transplantation.
Abu-Elmagd KM; Fung J; Draviam R; Shannon W; Jain A; Alessiani M; Takaya S; Venkataramanan R; Warty VS; Tzakis A
Transplant Proc; 1991 Dec; 23(6):2767-70. PubMed ID: 1721271
[No Abstract] [Full Text] [Related]
10. The effect of FK 506 on peripheral blood T-lymphocyte subsets in orthotopic liver transplant patients.
Yagihashi A; Yoshida Y; Terasawa K; Ujike Y; Konno A; Ogura K; Kobayashi M; Takenaka T; Hayashi S; Selby R
Transplant Proc; 1991 Dec; 23(6):2937-8. PubMed ID: 1721318
[No Abstract] [Full Text] [Related]
11. Cytomegalovirus and chronic allograft rejection in liver transplantation.
Gao LH; Zheng SS
World J Gastroenterol; 2004 Jul; 10(13):1857-61. PubMed ID: 15222023
[TBL] [Abstract][Full Text] [Related]
12. Recurrent rejection following FK 506 rescue therapy for acute hepatic allograft rejection.
Woodle ES; So S; Jendrisak MD; Perdrizet GA; White HM; Marsh JW
Transplant Proc; 1993 Apr; 25(2):1988-9. PubMed ID: 7682358
[No Abstract] [Full Text] [Related]
13. FK 506 rescue therapy: early conversion improves efficacy.
Woodle ES; Perdrizet GA; So S; Jendrisak MD; White HM; Marsh JW
Transplant Proc; 1993 Apr; 25(2):1990-1. PubMed ID: 7682359
[No Abstract] [Full Text] [Related]
14. Use of Prograf (FK 506) as rescue therapy for refractory rejection after liver transplantation. US Multicenter FK 506 Liver Study Group.
Klintmalm GB; Goldstein R; Gonwa T; Wiesner RH; Krom RA; Shaw BW; Stratta R; Ascher NL; Roberts JW; Lake J
Transplant Proc; 1993 Feb; 25(1 Pt 1):679-88. PubMed ID: 7679840
[TBL] [Abstract][Full Text] [Related]
15. Hepatic allograft rejection: new developments in terminology, diagnosis, prevention, and treatment.
Wiesner RH; Ludwig J; Krom RA; Hay JE; van Hoek B
Mayo Clin Proc; 1993 Jan; 68(1):69-79. PubMed ID: 8417259
[TBL] [Abstract][Full Text] [Related]
16. In vitro assessment of FK 506 immunosuppressive activity in transplant patients.
Zeevi A; Venkataramanan R; Warty V; Eiras G; Woan M; Abu-Elmagd K; Alessiani M; Jain A; Demetris AJ; Zerbe T
Transplant Proc; 1991 Dec; 23(6):2897-9. PubMed ID: 1721307
[No Abstract] [Full Text] [Related]
17. FK 506 rescue therapy: the rapidity of rejection reversal is related to the subsequent development of CMV disease.
Woodle ES; Perdrizet GA; So S; Jendrisak MD; White HM; Marsh JW
Transplant Proc; 1993 Apr; 25(2):1992-3. PubMed ID: 7682360
[No Abstract] [Full Text] [Related]
18.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
19.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
